- Sernova Corp. (SVA) has executed a partnership with Evotec SE to develop a cell therapy treatment for diabetic insulin users
- Evotec offered a license to Sernova for its Induced Pluripotent Stem Cell method
- The companies plan on developing an implantable insulin replacement therapy
- The novel therapy may be able to produce unlimited insulin for those living with diabetes
- They will split commercialization profits based on Evotec’s development funding
- Sernova Corp. (SVA) is unchanged trading at $1.57 per share as of 2:07 p.m. ET
Sernova (SVA) has announced a partnership with Evotec SE to develop a cell therapy treatment for diabetic insulin users.
Evotec has offered an exclusive license to Sernova for the use of its Induced Pluripotent Stem Cell (iPSC)-based beta cells to treat patients with diabetes.
The two companies plan on combining their technologies and expertise to develop an implantable iPSC-based beta cell replacement therapy.
According to Sernova, the novel therapy will be able to produce unlimited insulin for those living with diabetes.
Evotec will contribute its cell manufacturing capabilities tand will decide in the future on the joint funding of clinical development.
If the therapy meets commercialization, the companies agreed to a profit-sharing arrangement. The allocations are dependent on Evotec’s participation in funding the clinical development program.
According to Evotec, it has been able to demonstrate its reliability for producing an unlimited supply of stable beta cells using its method for producing cell clusters like the ones naturally produced in the human body.
Beta cell clusters are found in the pancreas and are responsible for the production of insulin.
“In tandem with our current clinical islet cell program, Sernova entered into multiple pharmaceutical research collaborations to identify the highest quality and most compatible iPSC cell technology and validate the cells preclinically within our Cell Pouch System,” said Dr. Philip Toleikis, President and CEO of Sernova.
Sernova Corp. (SVA) is unchanged trading at $1.57 per share as of 2:07 p.m. ET.